drugset / Trial / NCT05667402
Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
Central nervous system (CNS) leukemia is a poor prognostic factor for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thiotepa can penetrate the blood-brain barrier and has immunosuppressive effects and similar effects to irradiation in allo-HSCT. This project aims to investigate whether the TBF regimen is superior to the traditional modified BuCY2 regimen to improve the long-term survival of the CNS leukemia patients.
Timeline
- Start
- 2023-01-15
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ATG | Unknown | — | — |
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Comparator | Cytarabine | Small molecule | — | — |
| Subject | Fludarabine | Small molecule | — | — |
| Comparator | Lomustine | Small molecule | — | — |
| Subject | Thiotepa | Other / unclassified | — | — |
| Background | Busulfan | Small molecule | — | — |